TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03323034
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT01484717
Drug: transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants receive an 8 week supply of transdermal nicotine \[21 mg patches (4 wks), 14 mg (2 wks), 7 mg (2 wks)\].
Study: NCT00919607
Drug: quetiapine fumarate extended-release
Normalized name: QUETIAPINE FUMARATE 50 mg ORAL TABLET, EXTENDED RELEASE [Quetiapine Fumarate Extended-Release]
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200mg,oral,single dose
Study: NCT00919607
Drug: quetiapine fumarate extended-release
Normalized name: QUETIAPINE FUMARATE 50 mg ORAL TABLET, EXTENDED RELEASE [Quetiapine Fumarate Extended-Release]
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300mg,oral,single dose
Study: NCT04251026
Drug: tividenofusp alfa
Normalized name: Tividenofusp alfa
DrugBank: Tividenofusp alfa (DB17628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous repeating dose
Study: NCT02191033
Drug: Nicotine patch
Normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00190476
Drug: Weekly docetaxel alone
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00190476
Drug: Weekly docetaxel + cisplatin combination
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00982423
Drug: Furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects received their clinically prescribed dose of furosemide for a 3 week stabilization period, then were assessed for cardiorenal and humoral function. Subjects then had a 50% reduction of the furosemide dose for a 3 week stabilization period, and were assessed for cardiorenal and humoral function again.
Study: NCT02815540
Drug: Cannabidiol
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects who are planning to take state dispensed medical cannabidiol, or are already taking state dispensed medical cannabidiol.
Study: NCT01600170
Drug: Atorvastatin (generic Lipitor)
Normalized name: atorvastatin Oral Tablet [Lipitor]
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin is an FDA approved prescription drug which is frequently used to lower cholesterol levels.It is available in the form of tablets ranging in dose from 10-80mg.
Study: NCT01891227
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bendamustine 80mg/m2 will be administered on day 1 and 8 of a three week cycle (for a maximum of eight cycles).
Study: NCT01738282
Drug: Baclofen
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04268394
Drug: CC-99677
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-99677
Study: NCT04268394
Drug: Sulfasalazine
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfasalazine
Study: NCT04268394
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole
Study: NCT04268394
Drug: Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin
Study: NCT04268394
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam
Study: NCT00176267
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 75 mg/m2 intravenously over one hour on Days 1, 8, 15, 22, 29 and 36
Study: NCT00176267
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC of 6 on Days 1 \& 22
Study: NCT04460001
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal
Study: NCT04460001
Drug: triamcinolone acetate
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravitreal
Study: NCT04268394
Drug: Digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin
Study: NCT04268394
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin
Study: NCT02222246
Drug: Hydromorphone (Standardized, weight-based dosing)
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standardized analgesic management using a SCD specific standard protocol based on NHBLI guidelines (initial opioid dose weight-based).
Study: NCT02222246
Drug: Morphine Sulfate (Standardized, weight-based dosing)
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standardized analgesic management using a SCD specific standard protocol based on NHBLI guidelines (initial opioid dose weight-based).
Study: NCT02222246
Drug: Hydromorphone (Patient Specific dosing)
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient specific analgesic management, with specific opioid dosage and frequency based on a protocol developed by a patient's healthcare team.
Study: NCT02222246
Drug: Morphine Sulfate (Patient Specific dosing)
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient specific analgesic management, with specific opioid dosage and frequency based on a protocol developed by a patient's healthcare team.
Study: NCT00395395
Drug: Oral salmon calcitonin, salmon calcitonin nasal spray
DrugBank: Salmon calcitonin (DB00017)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02053376
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: regorafenib (120 mg) (160 mg for second and subsequent treatment cycles)orally once daily 21 days (3 weeks) on and 7 days (1 week) off in the 28-day (4-week) cycle.
Study: NCT04491474
Drug: Lidocaine Hydrochloride
Normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: While performing these procedures, 1 ml of 2% lidocaine hydrochloride and 1 ml of %0.9 saline will be used for creating a solution of 2 ml of 1% lidocaine for nerve block. Also 2 ml of saline will be used for placebo effect. For blocking the GON region 0.75 ml of 1% lidocaine will be applied and 0.75 ml of saline for placebo effect(8). During applying to the SON region 0.25 ml of 1% lidocaine for blockage and 0.25 ml of saline for placebo effect will be used(8). The GON injection site was planned to be 2 cm lateral and 2 cm below the occipital protrusion and the SON injection site was planned as the area with frontal incisor in the orbital arch
Study: NCT02494882
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02494882
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02494882
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00696826
Drug: sitagliptin phosphate
Normalized name: Sitagliptin Phosphate
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: sitagliptin phosphate 100 mg MK0431 (2 x 50 mg tablets) taken orally after overnight fast; Duration of Treatment: 5 Weeks
Study: NCT01885585
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00857688
Drug: Bismu-Jet
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth sodium tartrate, neomycin sulfate, procain hydrocloride
Study: NCT03602846
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prescribed with rapid acting, intermediate acting, mixed or long acting insulin.
Study: NCT02250157
Drug: Oratecan
Normalized name: Exatecan
DrugBank: Exatecan (DB12185)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01214733
Drug: tocilizumab [RoActemra/Actemra]
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8 mg/kg intravenously every 4 weeks in combination with allowed DMARDs
Study: NCT04066231
Drug: Erythromycin Lactobionate
Normalized name: Erythromycin Lactobionate
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Test model: Erythromycin has gastroprokinetic properties. The primary aim of this investigation is to validate the ability of the VIPUN GMS to discriminate between normal and pharmacologically-enhanced fasting gastric motility in healthy adults.~Erythromycin Lactobionate infusion: 200 mg i.v. infusion over a period of 20 minutes. Note: Erythromycin is not labeled as a gastroprokinetic agent in Belgium.
Study: NCT00030849
Drug: bexarotene
Normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04592666
Drug: Almonertinib
Normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: the standard therapy of single agent almonertinib
Study: NCT04592666
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: standard dose
Study: NCT04592666
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC=5
Study: NCT02544607
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine 0.5mg/kg over 40 minutes IV
Study: NCT01326611
Drug: Dextrose
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01580501
Drug: Tadalafil and Sildenafil
Normalized name: finasteride and tadalafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PDE-5 Inhibitor; Low dosages will be 0.5mg/kg and high dosages will be 1.0mg/kg
Study: NCT02541604
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab was administered as IV infusion (maximum 1200 mg) on Day 1 of each 21-day cycle.
Study: NCT01438827
Drug: Avanz Phleum pratense
Normalized name: Phleum pratense top
DrugBank: Phleum pratense top (DB14179)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension for Injection, Every 6 weeks for one year
Study: NCT00993148
Drug: maraviroc
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg tab by mouth once daily for 96 weeks
Study: NCT00993148
Drug: darunavir
Normalized name: Darunavir
DrugBank: Darunavir (DB01264)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 800 mg tab by mouth once daily for 96 weeks
Study: NCT00993148
Drug: ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100 mg capsule by mouth once daily for 96 weeks
Study: NCT03971422
Drug: Rozanolixizumab
Normalized name: Rozanolixizumab
DrugBank: Rozanolixizumab (DB14919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2.
Study: NCT01237769
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2200 IU/day
Study: NCT03287908
Drug: AMG 701
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive IV infusions of AMG 701.
Study: NCT03287908
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will receive oral capsules of pomalidomide.
Study: NCT03287908
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will receive IV injections or oral dexamethasone.
Study: NCT05993299
Drug: Letetresgene autoleucel
Normalized name: Letetresgene autoleucel
DrugBank: Letetresgene autoleucel (DB17233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letetresgene autoleucel will be administered.
Study: NCT05993299
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine will be used as a lymphodepleting chemotherapy.
Study: NCT02681549
Drug: Pembrolizumab plus Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab will be administered on day 1 of every cycle until disease progression or withdrawal from study. Bevacizumab will be administered in addition to pembrolizumab on day 1 of cycles 1, 2, 3, and 4 (or alternative cycles if bevacizumab is held during these cycles). Three weeks constitutes one cycle.
Study: NCT02970162
Drug: Amifampridine Phosphate
Normalized name: Amifampridine Phosphate
DrugBank: Amifampridine (DB11640)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04673396
Drug: Norcantharidin Lipid Microsphere for Injection
Normalized name: guggul lipids
DrugBank: Cantharidin (DB12328)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The test drug was added to 5% glucose injection to a final volume of 250 mL，and administered by instillation at a rate of 200 mL/h.~This product can be used alone or in combination with chemotherapy, and the dosage and time of administration vary with the chemotherapy regimen.
Study: NCT04673396
Drug: Sodium Demethylcantharidate Injection
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dissolve the reference drug with appropriate amount of sterile water for injection, and add 250 mL of 5% glucose injection for slow dripping.
Study: NCT02905890
Drug: Norethisterone enantate
Normalized name: Norethisterone enantate
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Noristerat® 200mg, solution for intramuscular injection given every 8 weeks
Study: NCT03991520
Drug: Anakinra 100Mg/0.67Ml Inj Syringe
Normalized name: ANAKINRA 100MG/0.67ML INJ SYRINGE
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The study drug is100mg/day Anakinra, which is the standard, FDA approved dose for the treatment of rheumatoid arthritis. The randomized treatment will be self-administered by the subject each evening by subcutaneous injection.
Study: NCT01940731
Drug: Colistimethate sodium
Normalized name: Colistimethate Sodium
DrugBank: Colistimethate (DB01111)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-5mg/(kg.d)(if CLcr≥80 mL/min),The maximum dose≤300mg/d 2.5-3.8mg/(kg.d)（if CLcr=50-79mL/min），The maximum dose≤230mg/d twice a day
Study: NCT03401502
Drug: Ranolazine
Normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral, b.i.d
Study: NCT02029898
Drug: sodium chloride 0,9%
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03603262
Drug: SH-1028
Normalized name: Glutathione-SH
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose 60mg,oral administered once daily.If tolerated subsequent cohorts will test increasing doses (100mg,200mg,300mg,400mg) of SH-1028.
Study: NCT00806819
Drug: Nintedanib (BIBF1120)
DrugBank: Nintedanib (DB09079)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
Study: NCT00806819
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.
Study: NCT00806819
Drug: pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.
Study: NCT00806819
Drug: B12
Normalized name: PB127
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1000 ug IM injection starting a week before first pemetrexed infusion and every 9 weeks thereafter until discontinuation of pemetrexed
Study: NCT01035021
Drug: use of rocuronium when the LMA is inserted
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthesia is induced with a propofol and remifentanil in both groups, however rocuronium 0.06 mg/kg is injected only in group R. Insertion of LMA is performed by the standard technique according to the manufacturer's instruction. In group N, rocuronium is administered for the operation.
Study: NCT02569502
Drug: enfuvirtide
Normalized name: Enfuvirtide
DrugBank: Enfuvirtide (DB00109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive a total daily dose of 180mg of enfurtide administered twice daily as a subcutaneous injection.
Study: NCT00806819
Drug: dexamethasone (or corticosteroid equivalent)
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4 mg PO bid the day before, the day of and the day after each pemetrexed infusion
Study: NCT01317199
Drug: Muscadine Plus Grape Skin Extract
Normalized name: muscadine grape extract
DrugBank: Grape (DB10533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase I: Dose escalation starts at 500mg pills given by mouth once daily for 28 days per cycle
Study: NCT01317199
Drug: Low-dose MPX
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Randomly-assigned participants receive one capsule of drug (500mg MPX) and seven capsules of placebo composed of pulverized rice, once daily for up to 12 cycles (28 days per cycle).
Study: NCT02484209
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin 1500 mg daily for 16 weeks
Study: NCT02484209
Drug: Glimepiride
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: glimepiride 2-4 mg twice daily for 16 weeks
Study: NCT03669783
Drug: treatment Actinomycin-D
Normalized name: ACTINOMYCIN-D
DrugBank: Dactinomycin (DB00970)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 x Actinomycin D 45µg/kg iv bolus day 1 in week 1, 3, 5
Study: NCT02484209
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: metformin 1500 mg daily for 16 weeks
Study: NCT03669783
Drug: treatment Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 x Carboplatin 200 mg/m² 1h infusion day 1,2,3 in week 1,4
Study: NCT03669783
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 x Etoposide 100mg/m² 1h infusion day 1,2,3 in week 1,4
Study: NCT01651637
Drug: synthetic surfactant (CHF5633)
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF5633 100 mg/kg; CHF5633 200 mg/kg synthetic surfactant sterile suspension in 3.0 ml glass vials with a total concentration of 80 mg/ml for intratracheal administration. Single administration
Study: NCT01996761
Drug: porcine brain peptide (Cerebrolysin)
Normalized name: Brain natriuretic peptide
DrugBank: .gamma.-brain natriuretic peptide (DB19026)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02831972
Drug: AG120
Normalized name: Ivosidenib
DrugBank: Ivosidenib (DB14568)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02831972
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00829504
Drug: Ropinirole HCl 0.25 mg Tablets
DrugBank: Ropinirole (DB00268)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 x 0.25 mg
Study: NCT02876601
Drug: Defibrotide
Normalized name: Defibrotide
DrugBank: Defibrotide (DB04932)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 6.25mg/kg bodyweight over 2h infusion
Study: NCT02876601
Drug: Lipopolysaccharide
Normalized name: Lipopolysaccharide
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bolus infusion of 2ng/kg bodyweight lps
Study: NCT04273035
Drug: Midazolam oral solution
Normalized name: midazolam Oral Solution
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral Buccolam
Study: NCT00357682
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg per day
Study: NCT00357682
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80mg per day
Study: NCT00357682
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300mg per day
Study: NCT04436497
Drug: Zilucoplan
Normalized name: Zilucoplan
DrugBank: Zilucoplan (DB15636)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Zilucoplan Administration: Subcutaneous injection~Dosage: 0.3mg/kg administered daily
Study: NCT02064582
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 160mg by mouth each day
Study: NCT02064582
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22.5 mg intramuscular every 3 months or 45mg intramuscular every 6 months
Study: NCT01590888
Drug: PBT2
Normalized name: Clioquinol
DrugBank: Clioquinol (DB04815)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250mg capsules administered orally once per day for 26 weeks
Study: NCT01590888
Drug: PBT2
Normalized name: Clioquinol
DrugBank: Clioquinol (DB04815)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg capsules administered orally once per day for 26 weeks
Study: NCT01065077
Drug: Cinaciguat (BAY58-2667)
Normalized name: Cinaciguat
DrugBank: Cinaciguat (DB16126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of 150 µg/h during 48h
Study: NCT01065077
Drug: Cinaciguat (BAY58-2667)
Normalized name: Cinaciguat
DrugBank: Cinaciguat (DB16126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of 100 µg/h during 48h
Study: NCT01065077
Drug: Cinaciguat (BAY58-2667)
Normalized name: Cinaciguat
DrugBank: Cinaciguat (DB16126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of 50 µg/h during 48h
Study: NCT04099589
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine/Cisplatin plus Toripalimab
Study: NCT03358017
Drug: Zoledronate
Normalized name: Zoledronate
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4 mg i.v. every 3/4 weeks for 6 months